Global Insights: Diffuse Large B-cell Lymphoma Therapeutics Market Expected to Surpass $6.92 Billion by 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Industry Valuation for the Diffuse Large B-cell Lymphoma Therapeutics Sector?
Recent years have seen substantial growth in the market size for therapeutics for diffuse large b-cell lymphoma. Expected to rise from $4.74 billion in 2024 to $5.1 billion in 2025, the market is projected to experience a compound annual growth rate (CAGR) of 7.5%. The growth during the historic period is credited to advancements in clinical research, regulatory approvals, enhanced patient awareness and diagnostic methods, collaborative partnerships, and the evolution of care standards.
Projected to witness strong expansion in the coming years, the market for diffuse large b-cell lymphoma therapeutics is predicted to escalate to $6.92 billion in 2029, growing at a compounded annual growth rate (CAGR) of 7.9%. This growth during the forecast period is primarily attributed to factors like the discovering of biomarkers, advancements in immunotherapy, rising stats of incidence rates, the world’s aging population, progress in healthcare infrastructure, and increasing access to novel medicines. The forecast period also considers significant trends such as the emergence of outpatient treatment environments, cooperative clinical trials, patient-focused care models, progress in diagnostic imagery, and the digitization of healthcare.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10805&type=smp
What Forces Are Driving The Growth Of The Diffuse Large B-cell Lymphoma Therapeutics Market?
Expectations for the growth of the diffuse large B-cell lymphoma therapeutics market are being driven by a rising prevalence of diffuse large B-cell lymphoma (DLBCL). This aggressive form of cancer develops from B-cells in the lymphatic system and is identified by its fast and widespread growth. It falls under the umbrella of non-Hodgkin lymphoma (NHL). By specifically targeting and managing cancer cells, the DLBCL therapeutics augment the outcomes for people who already have the diagnosis. As per the projections of the American Cancer Society, a not-for-profit health organization based in the US, around 80,550 individuals (44,880 men and 35,670 women) will be diagnosed with non-Hodgkin’s lymphoma (NHL) in 2023. Of these, approximately 20,180 individuals are expected to succumb to NHL. Thus, the escalating figures of DLBCL cases are fuelling the expansion of the diffuse large B-cell lymphoma therapeutics market.
How Is The Diffuse Large B-cell Lymphoma Therapeutics Industry Segmented Across Key Parameters?
The diffuse large b-cell lymphoma therapeutics market covered in this report is segmented –
1) By Drug Class: Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, Other Drugs
2) By Therapy: Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies
3) By Route of Administration: Oral, Parenteral, Other Routes
4) By End User: Hospitals, Clinics, Other End-Users
Subsegments:
1) By Cisplatin: Injection Formulations, Combination Therapies
2) By Carboplatin: Injection Formulations, Combination Therapies
3) By 5-Fluorouracil: Injection Formulations, Oral Formulations
4) By Docetaxel: Injection Formulations, Combination Therapies
5) By Paclitaxel: Injection Formulations, Combination Therapies
6) By Methotrexate: Injection Formulations, Oral Formulations, Combination Therapies
7) By Other Drugs: Monoclonal Antibodies, Targeted Therapies, Immunotherapies, Experimental Therapies
What Notable Trends Are Shaping The Direction Of The Diffuse Large B-cell Lymphoma Therapeutics Market?
A crucial trend emerging in the diffuse large B-cell lymphoma therapeutics market is the development of drug therapies. In a bid to consolidate their market standing, top companies in the diffuse large B-cell lymphoma therapeutics market are creating new therapeutic medications. Bristol-Myers Squibb, a US pharmaceutical company at the forefront of drug research and development, is a case in point. They received approval by the US FDA in June 2022 for their CAR T Cell Therapy Breyanzi. This therapy, intended for the treatment of patients with large B-cell lymphoma (LBCL), diffuse large B-cell lymphoma (DLBCL), and recurrent or resistant large B-cell lymphoma, is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. It’s suitable for a variety of patients suffering from primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and grade 3B follicular lymphoma.
Which Companies Currently Dominate The Competitive Landscape In The Diffuse Large B-cell Lymphoma Therapeutics Industry?
Major companies operating in the diffuse large B-cell lymphoma therapeutics market include Novartis AG, Pfizer Inc., Merck & Co Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche AG, CTI BioPharma Corp., Celltrion Healthcare Co Ltd., Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences Inc., Seagen Inc., Kite Pharma Inc., ADC Therapeutics SA, Bayer AG, Xencor Inc., Autolus Therapeutics plc, Allogene Therapeutics Inc., Spectrum Pharmaceuticals Inc., AstraZeneca PLC, Aptevo Therapeutics Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Celgene Corporation, Eli Lilly and Company, Sanofi SA, Seattle Genetics Inc., Karyopharm Therapeutics Inc., TG Therapeutics Inc., MorphoSys AG
Get The Full Report Here:
Which Geographic Regions Are Driving Demand In The Diffuse Large B-cell Lymphoma Therapeutics Market?
North America was the largest region in the global diffuse large B-cell lymphoma therapeutics market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diffuse large B-cell lymphoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10805&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
